Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.48 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897797 | 0.82 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL5759674 | 0.79 | TARBP2 (0.54) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL3530493 | 0.78 | RAB9A (0.53) | HSD17B10KDM4EALDH1A1TP53HPGD | |
| SCHEMBL5098582 | 0.78 | PPARG (0.62) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL5112529 | 0.77 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL6701051 | 0.77 | PPARG (0.58) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL1435701 | 0.76 | PPARG (0.62) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL5098317 | 0.76 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL5105446 | 0.76 | PPARG (0.60) | MAPTHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL6700515 | 0.75 | PPARG (0.59) | MAPTHSD17B10KDM4EALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414001-B2 | Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics | KOTOBUKI PHARMACEUTICAL CO. LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-20010008898-A1 | Ether and amide compounds and preparation of thereof as antidiadetics. | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2001-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008898-A1 | Ether and amide compounds and preparation of thereof as antidiadetics. | SLC5A2, GCG, NCEH1 | MAPT 4537/4885HSD17B10 322/4885KDM4E 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.